Rosuvastatin Calcium is used as the active pharmaceutical ingredient (API) in the production of oral rosuvastatin medications. This drug is indicated for the treatment of various lipid disorders, including primary hypercholesterolemia, mixed dyslipidemia, and familial hyperlipidemia. It is also recommended for reducing the risk of cardiovascular events in high-risk patients.
Rosuvastatin is one of the most potent statins and works by inhibiting the HMG-CoA reductase enzyme, effectively lowering LDL cholesterol and triglycerides while increasing HDL cholesterol. In addition to its lipid-lowering effects, rosuvastatin reduces vascular inflammation and stabilizes atherosclerotic plaques. Due to its high potency and comparatively low incidence of side effects, rosuvastatin is considered a first-line therapy for patients requiring significant cholesterol reduction.
Telmisartan is used as the active pharmaceutical ingredient (API) in the production of oral telmisartan medications for the management of hypertension, renal protection in diabetic patients with nephropathy, and reduction of cardiovascular event risk. It is also indicated for use in patients with heart failure.
Telmisartan belongs to the class of angiotensin II receptor blockers (ARBs) and works by inhibiting the effects of angiotensin II, leading to vasodilation and reduced blood pressure. In addition to controlling hypertension, telmisartan plays a crucial role in preventing kidney damage caused by diabetes and in reducing the risk of stroke and heart attack in high-risk patients.
The sacubitril-valsartan active pharmaceutical ingredient is utilized as the main active component in the manufacture of oral sacubitril-valsartan medication. Approved in 2015 by both the United States and the European Union, this combination drug is indicated for patients with chronic heart failure. Sacubitril-valsartan reduces the need for hospitalization due to severe heart failure and lowers mortality rates associated with the condition.
This product combines sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor type 1 blocker. The combination is sometimes referred to as an “angiotensin receptor-neprilysin inhibitor (ARNI).”